All Articles

Ensartinib (Ensacove; Xcovery Holdings, Inc) has been approved for use in treating adult patients with ALK-positive locally advanced or metastatic non–small cell lung cancer (NSCLC) who have not previously received an ALK inhibitor. Read More ›

Officials with the FDA have granted accelerated approval to encorafenib (Braftovi; Array BioPharma, a subsidiary of Pfizer) with cetuximab and mFOLFOX6 for patients with metastatic colorectal cancer with a ^BRAF V600E mutation, as detected by an FDA-approved test. Read More ›

Remestemcel-L-rknd (Ryoncil; Mesoblast), the first allogeneic bone marrow–derived mesenchymal stromal cell therapy, has been FDA-approved for steroid-refractory acute graft-versus-host disease (SR-aGVHD) in pediatric patients aged ≥2 months. Read More ›

Clinical trial recruitment and retention remain challenges in the quest to bring innovative therapies to all patients in need. Read More ›

A peer navigation model that addresses barriers in clinical trial participation and aims to boost enrollment in childhood cancer therapeutic clinical trials is underway, and one of the study researchers presented on the model at the 66th American Society of Hematology Annual Meeting & Exposition, held recently in San Diego, CA. Read More ›

The question remains: after 10 years of biosimilar availability in the United States and 20 years in Europe, are we there yet? Read More ›

A recent US-based study presented at the San Antonio Breast Cancer Symposium examined racial disparities in biomarker prevalence, treatment patterns, and clinical outcomes among Black and White patients with hormone receptor-positive/HER2-negative metastatic breast cancer who underwent next-generation sequencing. Read More ›

Clinical practice has evolved over time, and the doctor’s tools used in the past may no longer be the tools that are regularly utilized today. However, that brings up the question: what tools will healthcare utilize today or in the future? Read More ›

Next-generation sequencing of circulating tumor DNA (ctDNA) is integral to optimal cancer treatment, as exploring ctDNA can provide a complete picture of a tumor’s genetic landscape and can thus help guide treatment for the patient. The IMAGE II study (NCT02965755) investigated the clinical utility of serial ctDNA assessment in patients with metastatic breast cancer. Read More ›

Machine learning may hold promise for analyzing cells co-expressing MYC and BCL2 but lacking BCL6 in diffuse large B-cell lymphoma, which can be associated with poorer survival patterns, according to a study presented at the 66th ASH Annual Meeting & Exposition held in San Diego, CA. Read More ›